A Study of KW-3357 in Congenital Antithrombin Deficiency

Phase 1 Completed 16 enrolled Kyowa Kirin, Inc. Kyowa Hakko Kirin UK, Ltd. · collab

NaSingle-groupOpen-labelOther

Summary

The aim of this study is to determine the pharmacokinetics, safety and tolerability of KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.

Timeline

Start: 2009-04
Primary completion: 2010-12-22
Completion: 2011-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KW-3357	Protein / enzyme biologic	50 unknown	Intravenous

A Study of KW-3357 in Congenital Antithrombin Deficiency

Summary

Timeline

Drugs

Indications